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The resounding success of cisplatin in tumor therapy, in particular of testicular cancer, has set off tremendous efforts to produce other platinum drugs with comparable therapeutic value but devoid of its shortcomings (Wong and Giandomenico, 1999; Jakupec et al., 2003) . Despite the achievements of carboplatin and oxaliplatin, chances to bring about considerable advances with complexes following the classic structure-activity relationships seem to become gradually exhausted, forcing investigators to focus their efforts on non-classic structures that might open up new avenues.
The classic structure-activity relationships, as inferred from cisplatin/transplatin and related complexes, implied that the presence of two monodentate or one bidentate exchangeable ligand(s) coordinated in the cis geometry is an essential prerequisite for antitumor activity (Cleare and Hoeschele, 1973) . The pharmacological inactivity of transplatin had been attributed primarily to its inability to induce those DNA adducts that predominate in the case of cisplatin, i. e. intrastrand cross-links between adjacent purine bases, with a variety of consequences such as a different impact on DNA secondary structure, lower capacity of inhibiting replication and transcription, faster repair and the lack of recognition by high mobility group (HMG) domain proteins (Jamieson and Lippard, 1999) .
These assumptions have turned out to be too simplistic, since several exceptions from what had appeared as a rule have been recognized over the past years and repeatedly reviewed (e. g. Pérez et al., 2000; Natile and Coluccia, 2004) . However, no general criterion for considering a trans complex active has been used. Cytotoxicity higher than or at least equal to that of the corresponding cis isomer and/or that of cisplatin has mostly been taken as sufficient. Each of the following classes of active trans complexes recognized so far includes at least one representative with proved antitumor activity in an in vivo model: (i) platinum (II) complexes with aromatic N-heterocyclic ligands such as thiazole or quinoline (Farrell, 1996) ;
(ii) platinum(II) complexes with one or two iminoether ligands (Coluccia et al., 1995) ; (iii) platinum(IV) complexes with one ammine and one aliphatic amine ligand (Kelland et al., This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on October 18, 2006 as DOI: 10.1124 at ASPET Journals on July 7, 2017 molpharm.aspetjournals.org Downloaded from 1995); (iv) asymmetric platinum complexes with one branched aliphatic amine such as isopropylamine and another, non-bulky amine ligand (Pérez et al., 2003) ; and (v) cationic and neutral platinum(II) complexes with cycloaliphatic amines such as piperidine or piperazine (Najajreh et al., 2006) . Platinum(II) complexes with cyclic ligands mimicking iminoethers (Intini et al., 2004) and with acetimine ligands (Boccarelli et al., 2006) have been reported as a further classes, based on cytotoxicity data only.
Compounds of all these classes lack cross-resistance to cisplatin in cellular models of acquired cisplatin resistance (Farrell et al., 1992; Kelland et al., 1995; Coluccia et al., 1999; Pérez et al., 2003; Najajreh et al., 2006) . Furthermore, some of these compounds display a cytotoxicity profile that hardly correlates with that of cisplatin in the cell line panel of the NCI comprising cells from a wide variety of malignancies (Farrell, 1996) , and some even proved to be active in in vivo models with intrinsic or acquired resistance to cisplatin (Kelland et al., 1995; Coluccia et al., 1999) , raising the hope that an antineoplastic drug with a different clinical activity profile may emerge from these non-classic platinum agents.
Altered kinetics of DNA binding as compared to cisplatin and specific differences in DNA adduct patterns such as increased numbers and variant forms of interstrand cross-links, the formation of stable monofunctional DNA adducts and DNA-protein cross-links have been put forward as tentative explanations for the unexpected activity of these compounds. However, apparently none of these characteristics can be generalized to all active trans complexes, and subtle differences in adduct structure seem to result in a different cellular processing and different downstream effects leading to the manifestation of cytotoxicity (Brabec and Kasparkova, 2005) .
We report herein on a novel type of platinum(II) complexes of which the trans isomer, trans-[PtCl 2 (acetoxime) 2 ], 2 (trans) (Figure 1 ), displays a high cytotoxicity, whereas complexes of the type [PtCl 2 (hydroxylamine) 2 ] are shown to conform to the classic structure-activity relationships. Data on the reactivity of these complexes toward dGMP and the impact on This article has not been copyedited and formatted. The final version may differ from this version. with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 2 mM L-glutamine and 1% non-essential amino acids (100×) (all purchased from Gibco/Invitrogen, Paisley, UK).
Cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO 2 .
Cytotoxicity in cancer cell lines. Cytotoxicity was determined by means of a colorimetric microculture assay (MTT assay, MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). CH1 and SW480 cells were harvested from culture flasks by trypsinization and seeded into 96-well microculture plates (Iwaki/Asahi Technoglass, This article has not been copyedited and formatted. The final version may differ from this version. For incubation, a 20 mM HEPES buffer at physiological pH (7.4) and 37 °C was chosen.
Since HEPES absorbs in the UV range, a different buffer had to be used as background electrolyte (BGE) for the electrophoretic separations -a 20 mM phosphate buffer (pH 7.4) was utilized for this purpose. The incubation buffer and BGE were passed through a 0.45 µm This article has not been copyedited and formatted. The final version may differ from this version. again with water for 10 min each and then equilibrated with the BGE for 10 min. Before each injection, the capillary was purged with 0.1 M NaOH and water for 2 min each and finally conditioned with the BGE for 3 min.
The rate of binding to dGMP was measured by monitoring the decrease of the peak area response corresponding to the dGMP signal. The peak areas were normalized using the area of the incubation buffer signal as an internal standard. The kinetic series was repeated at least four times for each of the compounds.
In order to find an equation that most closely describes the behavior and character of kinetic curves and fits the experimental data, regression analysis was undertaken (natural logarithm of the dGMP concentration, i.e. its peak area, vs. time). Schematically, the first stage of reaction can be expressed as follows: 
The rate of the chemical reaction is determined by the slowest stage of the whole process. For bimolecular reactions, as written in eq. (1), the rate of the reaction can be expressed as
for its first stage, and for the second stage (assuming that [C] > [B] , and pseudo first order consequently):
where k 1 is the rate constant of the first stage, and k' 2 is a pseudo rate constant of the second stage of the reaction.
Preliminary estimations of the rate constants for the both stages have discovered that the rate constant of the first stage is much higher than the rate constant of the second stage. This means that the rate constant of the second stage determines the rate of the complete reaction, and in the following speculations we define k' 2 as the pseudo rate constant for the whole process (k bind ). Pseudo rate constants were calculated from fitted curves, half-lives were determined graphically.
This article has not been copyedited and formatted. The final version may differ from this version. For each time point of the kinetics analysis, 1 µg plasmid pTZ18u and 1.6 fmoles radioactively endlabeled 177 bp fragment and either one of the compounds at a final concentration of 60 µM were incubated separately in 40 µL 0.1× TE buffer (1 mM Tris-HCl, pH 7.5, 0.1 mM EDTA) at 37 °C. For detection of changes in DNA secondary structure, 5 µL 5× "blue juice" sample buffer (final: 2.5% glycerol, 0.5% SDS, 10 mM EDTA, 0.025% bromphenol blue, 0.025% xylene cyanol) were added to a 20 µL aliquot of a specific time point. The reaction products were separated immediately in a 1% agarose gel in TBE buffer at MOL #30726 12 mixed with 2.5 µL 5× "blue-juice" sample buffer. The samples were analyzed in a 4%
polyacrylamide gel in 1× TBE buffer, 0.1% SDS at 15 V/cm. After electrophoresis, the gel was fixed in 7% acetic acid, 4% glycerol for 20 min and dried for 2 h at 65°C under vacuum.
The gel was exposed to an X-ray film overnight at -70 °C. Analyses of DNA secondary structure and of DNA modification degree were performed at least 3 times with virtually identical results.
Interstrand cross-link (ICL) assay.
In order to analyze the ability of examined complexes to form ICLs, 0.8 fmoles radioactively endlabeled 177 bp fragment (see above) were incubated in 0.1× TE buffer as described above at a final concentration of 60 µM and a final volume of 20 µL per sample. After incubation, all samples were instantly evaporated to complete dryness in a speed vac and resuspended in 10 µL loading dye (98% formamide, 10 mM EDTA, 0.025% xylene cyanol, 0.025% bromphenol blue), heated for 3 min at 95°C and chilled in ice. The reaction products were separated in a denaturing 4% polyacrylamide gel, 7 M urea, 1× TBE, at 10 V/cm for 1 h. After fixing the gel in 7% acetic acid and 4% glycerol for 20 min and drying for 2 h at 65 °C under vacuum, it was exposed to an X-ray film at -70 °C for an appropriate time. ICL assays were repeated at least two times.
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Results
Cytotoxicity. The cytotoxic potencies of the acetoxime and hydroxylamine platinum complexes were compared with those of cisplatin and transplatin in the cisplatin-sensitive ovarian carcinoma cell line CH1 and the inherently cisplatin-resistant colon carcinoma cell line SW480 by means of the colorimetric MTT assay. IC 50 values are listed in Table 1 , and complete concentration-effect curves are depicted in Figure 2 .
In accord with ample evidence from the literature, transplatin is much less cytotoxic than cisplatin, though the difference between their potencies is much less pronounced in SW480 cells than in CH1 cells, which differ tremendously in their cisplatin sensitivity. In sharp contrast, the acetoxime complex 2 (trans) is roughly 15 times more potent than the corresponding geometric isomer 1 (cis) in both cell lines. In CH1 cells, the cytotoxicity of 2 (trans) is comparable to that of cisplatin, while it is even more potent than cisplatin in SW480 cells by an order of magnitude, indicating that the mechanisms causing the inherent cisplatin resistance of the latter cell line do not affect the activity of 2 (trans).
In the case of the hydroxylamine complexes, 3 (cis) is superior to 4 (trans), concordant with the classic structure-activity relationships derived from the cisplatin/transplatin couple. The differences between the cytotoxic potencies of 3 (cis) and 4 (trans) are similar to those between cisplatin and transplatin, their IC 50 values being shifted to higher concentrations, however. In contrast to acetoxime complex 1 (cis), hydroxylamine complex 3 (cis) closely parallels cisplatin insofar as a certain fraction of SW480 cells (up to 10%) resists rather high concentrations (3-12 times the respective IC 50 ), resulting in a characteristic shoulder in the concentration-effect curves (Figure 2 ), suggesting a yet unidentified resistance mechanism for both compounds.
This article has not been copyedited and formatted. The final version may differ from this version. Binding behavior toward dGMP. Capillary electrophoresis (CE) has often been applied to the analysis of platinum group complexes as well as their interaction with biomolecules over the recent years (Hartinger et al., 2003; Timerbaev et al., 2006) . DNA is considered the critical target for platinum complexes, and competitive studies including all four nucleobases confirmed guanine (and to a lesser extent adenine) as the preferred binding partner for the metal complexes -adduct formation takes place mainly via the N7 of the nucleobase (Martin, 1999) . Therefore, it was reasonable to compare the binding behavior of the complexes included in this study toward the model compound dGMP.
Reactivity decreases in the following order (based on the pseudo rate constants and the halflife of the dGMP peak): 3 (cis) > 4 (trans) > cisplatin > transplatin > 2 (trans) > 1 (cis) ( Table 2) . When comparing the binding kinetics of cis-and transplatin, it can be seen that transplatin reacts slightly faster than its cis analogue during the first hours of incubation.
Nevertheless, the reaction speed decreases, as the amount of trans-bound dGMP increases, indicating that the attachment of a second dGMP to the cis isomer is kinetically favored (Figure 3 ). This might be due to faster exchange of the second chloro ligand in cisplatin with water, because aquation is considered a prerequisite for adduct formation (Martin et al., 1999; Zenker et al., 2000) .
On the contrary, the acetoxime-containing complexes 1 (cis) and 2 (trans) show a different behavior: The trans isomer binds faster to dGMP than the cis form not only in the beginning but throughout the whole period of incubation. However, due to higher hydrolytic stability, binding progresses at a much slower rate as compared to the other compounds (Table 2 ). In the case of hydroxylamine-containing complexes 3 (cis) and 4 (trans), a similar observation as for cis-and transplatin can be made: Binding of one equivalent of dGMP progresses slightly faster for the trans compound, whereas the cis form shows stronger interaction toward a second dGMP, as reflected by the pseudo rate constant of the overall process.
This article has not been copyedited and formatted. The final version may differ from this version. In general, due to the complex nature of the reactions taking place in the sample simultaneously (aquation, oligomerization, dGMP binding), not all minor peaks in the electropherograms could be assigned to an exact structure. Anyhow, detection at 254 nm, analysis of the spectral patterns and migration times of the major peaks enabled us to clearly distinguish dGMP adducts (Figure 4 ) and therefore also determine pseudo rate constants and half-lives ( Table 2) .
Alterations of DNA secondary structure and reactivity with DNA. In order to examine the alterations of DNA secondary structure for the investigated compounds, kinetic studies of either one of the complexes with plasmid DNA were performed.
It is largely documented that platinum-based complexes can untwist, locally melt and/or bend dsDNA, depending on the kind of the specific adducts formed on DNA (Lepre and Lippard, 1990 ); for example, monofunctional or intercalating adducts may untwist dsDNA, whereas bifunctional adducts (intra-as well as interstrand cross-links), in addition, bend DNA.
Conversely, analyzing the DNA secondary structure may provide valuable clues about the kind of the DNA adducts. Changes of DNA secondary structures can be easily monitored by evaluating the electrophoretic migration pattern of a circular dsDNA plasmid in neutral agarose gels. Adducts that untwist dsDNA effect a slower migration of the negatively "supercoiled form" (sc) of the plasmid due to partial relief of the torsional stress and consequent relaxing of the compact sc form; a faster migration of the nicked, "open circular"
form (oc) of a plasmid, on the other hand, is consistent with adducts that compact or apparently "condense" dsDNA (Cohen et al., 1979) .
Hence, in order to examine the time-dependent alterations of DNA secondary structure for the investigated compounds, kinetic studies of the complexes with plasmid DNA were performed. Compound 2 (trans) ( Figure 5C ) is evidently more inefficient than compound 1 (cis) ( Figure   5A ) in inducing changes in DNA secondary structure. This may be due to either slower kinetics or to a weaker extent of structural changes at individual adducts (or both). However, the moderate shifting of the radioactively end-labeled dsDNA fragment in gel analysis shown in Figure 5D as compared to compound 1 (cis) ( Figure 5B ), reflecting a smaller DNA modification degree, reveals that the inefficacy of inducing changes in DNA secondary structure may be rather due to slower kinetics. Hence, the two isomers likely form adducts of comparable average impact on the DNA structure, albeit with different speed.
Besides the general ability of compound 1 (cis) to react with and induce changes in secondary structures of DNA faster than compound 2 (trans), an additional difference became visible.
By comparing the mobilization of the oc forms of the plasmid at nearly equivalent global
This article has not been copyedited and formatted. The final version may differ from this version. Figure 5C vs. lane 5 in Figure 5A ), it is obvious that bending (as defined above) induced by compound 2 (trans) is less pronounced. This might indicate that, if this bending is due to closure to bifunctional adducts of compound 2 (trans), this reaction is also kinetically impaired compared to compound 1 (cis).
The results of the interaction of plasmid DNA and a radioactively end-labeled dsDNA fragment with complexes of the hydroxylamine type, 3 (cis) and 4 (trans), are shown in Figure 6 . Both complexes displayed a much higher ability to induce changes in DNA secondary structure than the acetoxime compounds. Beyond 1 h or 2 h of incubation, respectively, compounds 3 (cis) and 4 (trans) untwisted the plasmid to positive supercoils.
The marked formation of adducts with plasmid DNA was accompanied by a distinctive shifting of the included DNA fragment for both compounds shown in Figures 6B and 6D . In addition, the 4 (trans) isomer showed a different migration behavior of the open circular form of the plasmid, analogous to the 2 (trans) isomer of the acetoxime type.
As a control, plasmid DNA was also incubated with cisplatin and transplatin. As expected, both compounds effected relaxation of the sc form and mobilization of the oc form of the plasmid, whereas transplatin showed a slightly higher efficiency to induce secondary structures as contrasted to cisplatin (Figure 7) . This parallels the known higher reactivity of transplatin against DNA (Farrell et al., 1992) . In accordance to the trans isomers 2 (trans) and 4 (trans), it is apparent that, at corresponding untwisting extent, the mobilization of the oc form of the plasmid caused by transplatin was less pronounced than that caused by cisplatin. and 4 (trans), the acetoxime platinum complexes 1 (cis) and 2 (trans) showed no formation of ICLs whatsoever for the investigated time points (1-7 h) (data not shown).
Discussion
We have discovered that trans-[PtCl 2 (acetoxime) 2 ], 2 (trans), is a new unconventional platinum compound violating the classic structure-activity relationship, insofar as its cytotoxicity is comparable with cisplatin in the ovarian carcinoma cell line CH1 and even superior to cisplatin by one order of magnitude in the rather cisplatin-insensitive colon carcinoma cell line SW480, indicating a potential of overcoming primary cisplatin resistance.
This again emphasizes the great relevance of active trans complexes for the development of new platinum-based anticancer drugs, since non-cross-resistance to cisplatin is common to most of these compounds. The observation that 2 (trans) is 15-16 times more cytotoxic than 1 (cis) is striking, since the cis counterparts of active trans complexes investigated by other authors are not substantially less active (e. g. Farrell et al., 1992; Farrell, 1996) , indicating that the substitution of ammine by appropriate ligands usually activates the trans geometry without severely impairing the activity of the cis congener. Hence, this is, to our knowledge, the first successful reversion of the structure-activity relationship of the cis and trans geometry.
A synopsis with the active trans-platinum complexes reported by other authors (see Introduction) reveals that 2 (trans) shares with both iminoether and acetimine complexes the azomethine moiety C=N and the planarity around the nitrogen donor atom resulting from its sp 2 hybridization. This also applies to N-heterocyclic complexes, but the involvement of the nitrogen donor atom in an aromatic ring system strongly distinguishes them from the former. While the acetoxime complex 2 (trans) resembles the acetimine complexes of Natile and coworkers (Boccarelli et al., 2006) in two crucial respects, i. e. the planar azomethine and the branched aliphatic moiety, it differs from them (and from all other examples of active transplatinum complexes) by the formal substitution of the nitrogen-bound hydrogen by hydroxyl groups. Since this renders the compound a stronger H-bonding donor than conventional amine complexes, an involvement of hydrogen bonding in the DNA interactions, e. g. in stabilizing monofunctional adducts, should be considered. Moreover, the OH acidity of the metal-bound acetoximes is significant (pK a1 6-7) (Kukushkin et al., 1996) , but although this acidity constitutes a major difference to other active trans-platinum complexes, the sole presence of a hydroxyl group bound to the nitrogen donor atom is neither sufficient nor essential for activity of the trans isomer, as can be inferred from the classic structure-activity relationship of the [PtCl 2 (hydroxylamine) 2 ] couple, 3 (cis) and 4 (trans).
The reactivity of the compounds has been investigated by monitoring the reaction with dGMP and with a DNA fragment. Although 2 (trans) was the least reactive with DNA, it was the most cytotoxic of the investigated compounds. The fact that slowly reacting compounds display a rather strong cytotoxicity or, inversely, that strongly reacting compounds may be devoid of biologic activity is striking but not new or astonishing. For instance, it has been repeatedly shown that transplatin reacts about 2.5-fold more efficiently than cisplatin with both calf thymus and plasmid DNA (see e. g. Farrell et al., 1992) , yet without favorable impact on its cytotoxicity. Likewise, the cytotoxity of transdichlorobis(E-iminoether)platinum(II), trans-EE, which is closely related to 2 (trans), is comparable to cisplatin in the P388 leukemia system (Coluccia et al., 1995) , although cisplatin displays significantly faster reaction kinetics with calf thymus DNA than trans-EE (Coluccia et al., 1995; Žaludová et al., 1997) . It may be that efficient reaction of a compound This article has not been copyedited and formatted. The final version may differ from this version. even with the cellular DNA cannot bring about increased cytotoxicity, if its adducts are rapidly removed by repair systems. Instead, formation of repair-resistant adducts that actively lead to programmed cell death is critical for the activity of the compounds (Zorbas and Keppler, 2005) . Hence, the cytotoxicity of active trans isomers in general and, in particular, the isomer 2 (trans) investigated in this study may, therefore, rely on the formation of particularly potent adducts.
In fact, the cytotoxic power of platinum complexes has been associated with adducts that induce particular secondary structures of DNA (Eastman, 1999; Kartalou and Essigmann, 2001 ). We found that our novel compounds were able to induce changes of DNA structure, namely visible DNA relaxation and DNA condensation. Relaxation of the scDNA was obviously effected by local untwisting at the sites of adducts. In accord to numerous investigations of platinum compounds, the detected untwisting is consistent with formation of monofunctional adducts at purine nucleobases. Hence, the compounds of both types (hydroxylamine and acetoxime) may form monofunctional adducts. Condensed circular DNA modified with platinum complexes, first described for cisplatin and transplatin by Cohen et al. (Cohen et al., 1979) , was recognized by Bellon et al. as caused by multiple, rigid or flexible bends not in phase with the DNA periodicity leading to apparent diminished diameter of circular DNA (Bellon et al., 1991; Bellon and Lippard, 1990) . We cannot distinguish between the two variants of bending, stable or flexible, in this study. Bending may be caused by bifunctional adducts, either intra- (Takahara et al., 1995) or interstrand (Huang et al., 1995) cross-links. In addition, some compounds with the trans geometry have been reported to effect bending by monofunctional coordination Novakova et al., 2003; Zakovska et al., 1998) , although, at least for the trans compounds with heterocyclic ligands, (stacking) interactions of these ligand(s) with DNA were also discussed, which might give rise to "pseudobifunctional" adducts (Zakovska et al., 1998 We observed that the induced condensation of the oc form was less pronounced with all investigated trans isomers than with all investigated cis isomers at comparable global untwisting, best visible with the pair 1 (cis)/2 (trans) ( Figure 5 ). If bifunctional adducts were the cause of bending, this might be an indication of a slower reaction of the second platinum valence of the trans isomers as compared to the cis isomers. Interestingly though, the same observation has been made with trans-vs. cis-EE (see Fig. 5 in Žaludová et al., 1997) , i. e.
with a structurally similar, also active trans compound that is known to cause bending by abundant monofunctional adducts . By analogy hence, it is tempting to speculate, that in our case bending might have been effected by monofunctional adducts as well. This, however, will by subject of future studies.
Which structural feature might constitute the high cytotoxicity of our active compounds?
Intrastrand cross-links, like the 1,2-d(GpG) adduct of cisplatin, which displays unique structural features of which the main characteristic is a rigid, directed bend of 30-35 degrees into the major groove of dsDNA (Jamieson and Lippard, 1999) , may be important cytotoxic lesions. On the other hand, ICLs, although minor adducts in general (e. g. ~2% of all cisplatin adducts), have never been excluded as possible lethal lesions of platinum complexes. In fact,
ICLs may be equally important cytotoxic adducts under certain conditions like intrastrand adducts (Aloyz et al., 2002; Zdraveski et al., 2000) . 3 (cis) and 4 (trans) readily form ICLs.
Since 3 (cis) displays a rather fairly high cytotoxicity, we cannot exclude that, in this case, ICLs seem definitely to be not necessary for the superb cytotoxic activity of the 2 (trans).
Interestingly, the highly cytotoxic and antitumoral trans-EE was also found to have a very small DNA interstrand cross-linking efficacy (Coluccia et al., 1995; Žaludová et al., 1997) .
If monofunctional adducts constitute a major fraction of the 2 (trans) lesions, they may contribute significantly to cytotoxicity as well. As was shown for monofunctional adducts of trans-EE , proteins like histone H1 may be readily captured by the available valence of the platinum giving rise to ternary DNA-drug-protein complexes. Such Products of a linear, radioactively labeled 177 bp DNA fragment after incubation with 60 µM compound 3 (cis) (A) and compound 4 (trans) (B), respectively, for the indicated time points (lanes 2-8) and electrophoretic separation in a denaturing 4% polyacrylamide gel; the panels depict the autoradiograph of the dried gels. C (lanes 1), control DNA, not incubated; C (lanes 9), control DNA, incubated for 3 hours.
